VANCOUVER BC / ACCESSWIRE / February 10, 2021 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving patients through medical centres, telemedicine platforms, operating a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce it has secured Medical Device Establishment Licence (“MDEL”) status to sell its KAI Medical COVID-19 Saliva Test kits (“KAI Saliva”).
KAI Saliva is FDA EUA approved for use, has CE Mark and the saliva specimen collection device is approved by Health Canada. KAI Saliva provides travellers, both foreign and domestic with a simple, fully compliant method to obtain an RT-PCR test and test result prior to arriving or coming back into to Canada or arriving to other countries that have similar executive travel orders.
EMPOWER ACCELERATES ABILITY TO DISTRIBUTE AND SELL MEDICAL DEVICE PRODUCTS IN CANADA THROUGH PARTNERSHIP WITH MEDIPRO CANADA
Empower previously announced the filing of an MDEL application for the purpose of importing, distributing and selling KAI Saliva, which has experienced success upon its launch.
To accelerate the process, Empower partnered with MediPro Canada Inc. (“MediPro”) to utilize their approved MDEL status. MediPro provides healthcare products for governments, large corporations and medical facilities around the world and is led by Hon. Sheila Maureen Copps PC OC.
“We continue to see extensive demand for novel COVID-19 testing products in both private sector and public sector markets throughout North America, Mexico and Caribbean countries.” said Hon. Sheila Copps OC, Partner MediPro Canada. “Leveraging the vast network of MediPro Canada with the integrated healthcare capabilities of Empower Clinics and their novel COVID-19 testing products, makes for an ideal partnership.”
“We all have an urgent requirement for a home-based, self-administered COVID-19 saliva test kit that can help open up the economy and facilitate travel that meets the requirements of the executive travel orders.” said Steven McAuley, Chairman & CEO. “We also must utilize our resources, our reach, our capability, do everything we can to assist, be humanitarians, use our voice, strive to provide improved healthcare, and lead the path of progressive healthcare.”
HIGHLY VIABLE SOLUTION FOR AIRLINE PASSENGERS, BOTH DOMESTIC AND FOREIGN, TO TRAVEL TO AND FROM CANADA
KAI Saliva can provide travellers a simple, compliant method to obtain an RT-PCR test and result prior to arriving in to or back-into Canada.
KAI Saliva can provide major airlines, cruise lines and the tourism sector with the ability to provide solutions for travellers by making a KAI Saliva purchase part of the ticketing purchase, the check-in process, in a kiosk, or on an e-commerce website. Foreign travellers could receive and take the test in their home countries, while Canadian travellers could take KAI Saliva with them on their trip to self-administer, send, then receive their secure test result prior to boarding their flight.
This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics
ABOUT MEDIPRO CANADA INC.
Medipro Canada Inc. provides the highest quality healthcare products for governments, large corporations and medical facilities. With our contacts of medical suppliers internationally, we source the highest most effective standardized medical supplies and devices in the market today. Our reputation of supplying the most reliable PP + PE protection against diseases and viruses globally is unsurpassed and delivered on time to clients.
Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.
ON BEHALF OF THE BOARD OF DIRECTORS:
Chief Executive Officer
Business Development & Communications
DISCLAIMER FOR FORWARD-LOOKING STATEMENTS
This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; launch of new healthcare centers and the occurrence thereof; that the Company can bring healthcare to millions of Canadians; that new healthcare services can be added and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.